Cypress Bioscience, Inc. trades in the stock market as ticker CYPB. Business Summary & Profile For Cypress Bioscience, Inc..
Cypress Bioscience, Inc.
Cypress Bioscience, Inc. develops and commercializes pharmaceutical products and personalized medicine laboratory services to rheumatologists in the United States. The company is developing milnacipran, norepinephrine serotonin reuptake inhibitor for fibromyalgia syndrome. The milnacipran is a dual-reuptake inhibitor that preferentially blocks the reuptake of norepinephrine. It has collaboration/license agreements with Collegium Pharmaceutical, Inc.; Forest Laboratories, Inc.; and Pierre Fabre. The company was founded in 1981 and is based in San Diego, California.
Stock Ticker Cloud
|No related news found for this Cypress Bioscience, Inc..|
Get our Stock Market & financial investment news alerts in your inbox